Orchestra BioMed
OBIO
56 hedge funds and large institutions have $81.3M invested in Orchestra BioMed in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
6% more capital invested
Capital invested by funds: $77M → $81.3M (+$4.28M)
4% more funds holding
Funds holding: 54 → 56 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.68% less ownership
Funds ownership: 50.65% → 49.97% (-0.68%)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
+$415K |
| 2 |
State Street
Boston,
Massachusetts
|
+$129K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$114K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$104K |
| 5 |
MCM
Massar Capital Management
Stamford,
Connecticut
|
+$49.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Boxer Capital Management
San Diego,
California
|
-$953K |
| 2 |
JP Morgan Chase
New York
|
-$186K |
| 3 |
BlackRock
New York
|
-$165K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$134K |
| 5 |
Morgan Stanley
New York
|
-$96.9K |
OBIO Hedge Fund Activity: Q1 2025 in Review
56 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2025, worth a combined $81.3M — up 5.6% from $77M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new OBIO positions and 4 closed out — a net gain of 2 holders — while 16 added to existing stakes and 18 trimmed.
The largest buyer was IFP Advisors, adding an estimated $415K. The largest seller was Boxer Capital Management, exiting entirely with an estimated $953K sold.
- 56 institutional investors held Orchestra BioMed (OBIO) as of Q1 2025, up from 54 in Q4 2024.
- Funds reported $81.3M of Orchestra BioMed stock for Q1 2025, up 5.6% quarter-over-quarter.
- 6 funds opened new Orchestra BioMed positions in Q1 2025 and 4 closed out, a net change of +2 holders.
- The largest Orchestra BioMed buyer in Q1 2025 was IFP Advisors, an estimated $415K added.
- The largest Orchestra BioMed seller in Q1 2025 was Boxer Capital Management, an estimated $953K sold.
Based on aggregated 13F filings for Q1 2025.